Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.

Efstathios Kastritis, MD, Athanasios Anagnostopoulos, MD, Maria Roussou, MD, Savvas Toumanidis, MD, Constantinos Pamboukas, MD, Anna Tassidou, MD, Irini Xilouri, MD, Sossana Delimpassi, MD, Erasmia Psimenou, MD, Sofia Mellou, MD, Evangelos Terpos, MD, John Nanas, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 191.

https://doi.org/10.1182/blood.V110.11.191.191

Published: 2007

Journal Articles

The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).

Blood (2007) 110 (11): 1490.

https://doi.org/10.1182/blood.V110.11.1490.1490

Published: 2007

Journal Articles

Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.

Maria Roussou, MD, Efstathios Kastritis, MD, Athanasios Anagnostopoulos, MD, Evangelos Eleftherakis-Papaiakovou, MD, Charis Matsouka, MD, Despina Barmparousi, MD, Magdalini Migkou, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 4812.

https://doi.org/10.1182/blood.V110.11.4812.4812

Published: 2007

Journal Articles

Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.

Maria Roussou, MD, Efstathios Kastritis, MD, Athanasios Anagnostopoulos, MD, Erasmia Psimenou, MD, Irini Grapsa, MD, Charis Matsouka, MD, Despina Barmparousi, MD, Evangelos Terpos, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 2739.

https://doi.org/10.1182/blood.V110.11.2739.2739

Published: 2007

Journal Articles

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia

Partow Kebriaei, Michelle A. Detry, Sergio Giralt, Antonio Carrasco-Yalan, Athanasios Anagnostopoulos, Daniel Couriel, Issa F. Khouri, Paolo Anderlini, Chitra Hosing, Amin Alousi, Richard E. Champlin, Marcos de Lima

Blood (2007) 110 (9): 3456–3462.

https://doi.org/10.1182/blood-2007-04-085969

Published: 2007

Journal Articles

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A. Dimopoulos, MD, Athanasios Anagnostopoulos, M.D., Marie Christine Kyrtsonis, M.D., Constantinos Tsatalas, M.D., Garyfallia Kokkini, M.D., Panagiotis Repoussis, M.D., Athanasios Zomas, M.D., Argiris Symeonidis, M.D., Evridiki Michali, M.D., Nikolaos Anagnostopoulos, M.D., Evangelos Terpos, M.D., Theophanis Economopoulos, M.D., Gerasimos Pangalis, M.D.

Blood (2006) 108 (11): 128.

https://doi.org/10.1182/blood.V108.11.128.128

Published: 2006

Journal Articles

Pulsed Cyclophoshamide, Thalidomide and Dexamethasone (CTD) Regimen for Previously Treated Patients with Multiple Myeloma: Long Term Follow up and Disease Control after Subsequent Treatments.

Maria Roussou, MD, Athanasios Anagnostopoulos, M.D., Efstathios Kastrtis, M.D., Charis Matsouka, M.D., Despina Barmparoussi, M.D., Vasiliki Koutsoukou, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 3565.

https://doi.org/10.1182/blood.V108.11.3565.3565

Published: 2006

Journal Articles

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).

Athanasios Anagnostopoulos, MD, Lia A. Moulopoulos, M.D., Maria Roussou, M.D., Efstathios Kastritis, M.D., Dimitra Gika, George Bozas, M.D., Aikaterini Stefanoudaki, M.D., Nikolaos Anagnostopoulos, M.D., Amalia Vassou, M.D., Konstantinos Bourantas, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 3095.

https://doi.org/10.1182/blood.V108.11.3095.3095

Published: 2006

Journal Articles

Dysfunction of Toll-Like Receptor-2, −4, and −6: Is There a Role in the Pathogenesis of Immunodeficiency in Multiple Myeloma?.

Evangelos Terpos, Meletios A. Dimopoulos, Charoula Xirakia, Dimitrios Christoulas, Athanasios Anagnostopoulos, Eirini Katodritou, Kostas Zervas, Paschalis Sideras, Konstantinos Tsionos, Evangelos Andreakos

Blood (2006) 108 (11): 3430.

https://doi.org/10.1182/blood.V108.11.3430.3430

Published: 2006

Journal Articles

Treatment of Low-Grade Non-Hodgkin Lymphomas with Fludarabine and Mitoxantrone Followed by Rituximab Maintenance: Results of a Phase II Study.

Amanda Psyrri, MD, Meletios A. Dimopoulos, MD, George Fountzilas, MD, Constantinos Tsatalas, MD, Athanasios Anagnostopoulos, MD, Sotirios Papageorgiou, MD, Nikolaos Xiros, MD, Theofanis Economopoulos, MD

Blood (2006) 108 (11): 4716.

https://doi.org/10.1182/blood.V108.11.4716.4716

Published: 2006

Journal Articles

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.

Evangelos Terpos, Athanasios Anagnostopoulos, Deborah Heath, Efstathios Kastritis, Dimitrios Christoulas, Nikolaos Anagnostopoulos, Maria Roussou, Konstantinos Tsionos, Peter Croucher, Meletios A. Dimopoulos

Blood (2006) 108 (11): 3541.

https://doi.org/10.1182/blood.V108.11.3541.3541

Published: 2006

Journal Articles

Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma Treated with High-Dose Dexamethasone Containing Regimens and the Impact of Novel Agents.

Efstathios Kastritis, MD, Athanasios Anagnostopoulos, M.D., Aristotle Bamias, M.D., Maria Roussou, M.D., Dimitra Gika, M.D., Vassiliki Koutsoukou, M.D., Charis Matsouka, M.D., Despina Barmparousi, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 3586.

https://doi.org/10.1182/blood.V108.11.3586.3586

Published: 2006

Journal Articles

Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML).

Partow Kebriaei, MD, Michelle Detry, PhD, Antonio Carrasco-Yalan, MD, Athanasios Anagnostopoulos, MD, Daniel Couriel, MD, Issa Khouri, MD, Paolo Anderlini, MD, Chitra Hosing, MD, Amin Alousi, MD, Sergio Giralt, MD, Richard Champlin, MD, Marcos de Lima, MD

Blood (2006) 108 (11): 2898.

https://doi.org/10.1182/blood.V108.11.2898.2898

Published: 2006

Journal Articles

Melphalan-Induced DNA Damage In Vitro as Predictor for Clinical Outcome in Multiple Myeloma.

Meletios A. Dimopoulos, MD, Vassilis L. Souliotis, PhD, Athanasios Anagnostopoulos, M.D., Christina Bamia, PhD, Anastasia Pouli, M.D., Ioannis Baltadakis, M.D., Evangelos Terpos, M.D., Soterios A. Kyrtopoulos, PhD, Petros P. Sfikakis, M.D.

Blood (2006) 108 (11): 60.

https://doi.org/10.1182/blood.V108.11.60.60

Published: 2006

Journal Articles

Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma.

Evangelos Terpos, Lia A. Moulopoulos, Athanasios Anagnostopoulos, Efstathios Kastritis, Maria Roussou, Vangelis Eleftherakis-Papaiakovou, Despina Barmparousi, Charis Matsouka, Meletios A. Dimopoulos

Blood (2006) 108 (11): 5018.

https://doi.org/10.1182/blood.V108.11.5018.5018

Published: 2006

Journal Articles

Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.

Evangelos Terpos, Deborah Heath, Amin Rahemtulla, Kostas Zervas, Andrew Chantry, Athanasios Anagnostopoulos, Anastasia Pouli, Eirini Katodritou, Evgenia Verrou, Elisavet C. Vervessou, Meletios A. Dimopoulos, Peter Croucher

Blood (2006) 108 (11): 506.

https://doi.org/10.1182/blood.V108.11.506.506

Published: 2006

Journal Articles

Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance.

Vangelis Eleftherakis-Papaiakovou, MD, Athanasios Anagnostopoulos, M.D., Aristotelis Bamias, M.D., Dimitra Gika, Argiris Symeonidis, M.D., Anastasia Pouli, M.D., Nikolaos Anagnostopoulos, M.D., Konstantinos Zervas, M.D., Evridiki Michali, M.D., Efstathios Kastritis, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 5000.

https://doi.org/10.1182/blood.V108.11.5000.5000

Published: 2006

Journal Articles

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom’s Macroglobulinemia (WM): Correlations with Clinical Data.

Athanasios Anagnostopoulos, MD, Evangelos Terpos, M.D., Konstantinos Zervas, M.D., Efstathios Kastritis, M.D., Vangelis Eleftherakis-Papaiakovou, M.D., Irini Katodritou, M.D., Konstantinos Tsionos, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 5006.

https://doi.org/10.1182/blood.V108.11.5006.5006

Published: 2006

Journal Articles

VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.

Konstantinos Zervas, MD, Dimitra Mihou, M.D., Irini Katodritou, M.D., Anastasia Pouli, M.D., Chrisanthi H. Mitsouli, M.D., Athanasios Anagnostopoulos, M.D., Souzana Delimbasi, M.D., Marie-Christine Kyrtsonis, M.D., Nikolaos Anagnostopoulos, M.D., Evangelos Terpos, M.D., Panagiotis Zikos, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 794.

https://doi.org/10.1182/blood.V108.11.794.794

Published: 2006

Journal Articles

Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia

Steven P. Treon, Morie A. Gertz, Meletios Dimopoulos, Athanasios Anagnostopoulos, Joan Blade, Andrew R. Branagan, Ramon Garcia-Sanz, Stephen Johnson, Eva Kimby, Veronique LeBlond, Jean-Paul Fermand, David G. Maloney, Giampaolo Merlini, Pierre Morel, Enrica Morra, Gwen Nichols, Enrique M. Ocio, Roger Owen, Marvin J. Stone

Blood (2006) 107 (9): 3442–3446.

https://doi.org/10.1182/blood-2005-02-0833

Published: 2006

NARROW

Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.

The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).

Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.

Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Pulsed Cyclophoshamide, Thalidomide and Dexamethasone (CTD) Regimen for Previously Treated Patients with Multiple Myeloma: Long Term Follow up and Disease Control after Subsequent Treatments.

Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).

Dysfunction of Toll-Like Receptor-2, −4, and −6: Is There a Role in the Pathogenesis of Immunodeficiency in Multiple Myeloma?.

Treatment of Low-Grade Non-Hodgkin Lymphomas with Fludarabine and Mitoxantrone Followed by Rituximab Maintenance: Results of a Phase II Study.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.

Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma Treated with High-Dose Dexamethasone Containing Regimens and the Impact of Novel Agents.

Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML).

Melphalan-Induced DNA Damage In Vitro as Predictor for Clinical Outcome in Multiple Myeloma.

Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma.

Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.

Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance.

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom’s Macroglobulinemia (WM): Correlations with Clinical Data.

VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.

Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only